重组人血管内皮抑制素联合卡铂与依托泊苷治疗晚期小细胞肺癌的临床观察  

Clinical observation of recombinant human endostatin combined with carboplatin and etoposide for advanced small-cell lung cancer

作　　者：陈建华[1,2] 罗永忠 周文伟[1,2] 周辉 王伟[1,2] 

机构地区：[1]湖南省肿瘤医院 [2]中南大学湘雅医学院附属肿瘤医院肿瘤内科,湖南长沙410013

出　　处：《实用临床医药杂志》2013年第5期26-28,共3页Journal of Clinical Medicine in Practice

基　　金：中国高校医学期刊临床专项资金(11320038)

摘　　要：目的研究重组人血管内皮抑制素联合卡铂与依托泊苷方案(CE方案)治疗晚期小细胞肺癌的临床疗效。方法将43例晚期小细胞肺癌患者随机分为2组,对照组24例给予CE方案化疗,观察组19例在CE方案基础上加用重组人血管内皮抑制素。治疗2个周期后,比较2组患者的疗效及安全性。结果观察组和对照组的缓解率、中位无进展时间分别为84.2%、50.0%和7.9、6.1个月,2组比较差异显著;观察组和对照组的中位生存期分别为11.1和11.0个月,差异无统计学意义;2组患者化疗药物毒副作用比较,差异无统计学意义。结论重组人血管内皮抑制素联合CE方案治疗晚期小细胞肺癌具有较好的近期疗效和耐受性。Objective To study the clinical effects of recombinant human endostatin com- bined with carboplatin and etoposide regime （CE regime） in the treatment of advanced small - cell lung cancer. Methods Forty - three patients with advanced small - cell lung cancer were randomly divided into control group and observation group. The control group （n = 19） was administered CE regime, whereas the observation group （n = 24） was added with recombinant human endostatin based on CE regime. After 2 cycles of treatment, the clinical effects and safety of 2 groups were compared. Results The remission rates and median progression-free survivals （MPFS） of the ob- servation group and the control group were respectively 84.2 % and 50.0 % as well as 7.9 months and 6.1 months, and there were both significant differences between both groups. The median survival time （MST） of 2 groups was 11.1 months and 11.0 months, respectively, but there was no significant difference. There was also no marked difference between both groups in terms of toxic and side effects exerted by chemotherapeutics. Conclusion In the treatment of advanced small - cell lung cancer, recombinant human endostatin combined with CE regimen has better short - term therapeutic effects and tolerance.

关 键 词：小细胞肺癌 重组人血管内皮抑制素 卡铂 依托泊苷 

分 类 号：R734.2[医药卫生—肿瘤]